Making Organ Transplants Work Longer

Globally, there is a persistent shortage of viable organs for transplantation. This unmet need has spurred the development of “engineered organs” — cultivated tissue that mimics the structure and function of livers, hearts, lungs and other vital viscera.

While these in-vitro inside parts can be used to fill the gap in organ supply, it’s really hard to supply blood throughout the newly transplanted tissue.

To solve this problem, Bonus Biogroup, an Israeli biotechnology company specializing in next-generation tissue regeneration therapies, has developed a method of producing a sophisticated network of artificial blood vessels that will enable reliable blood flow to transplanted artificial organs, drastically increasing their viability.

Keep reading at israel21c.org.

Bonus BioGroup Founder, CEO, and President Shai Meretzki, COO Dror Ben-David, and VP of R&D Atara Novak are all Technion alumni.